NEJM:左旋多巴对帕金森疾病的改善研究

2019-01-24 zhangfan MedSci原创

研究认为,左旋多巴联合甲基多巴肼对早期帕金森患者无疾病治疗作用

左旋多巴是缓解帕金森病患者临床症状的重要药物,近日研究人员就左旋多巴对疾病本身的治疗效果进行了考察。

早期帕金森患者参与研究,随机接受每日3次,每次100mg的左旋多巴+每日3次,每次25mg的甲基多巴肼持续80周(提前治疗组)或先接受40周的安慰剂,随后接受40周的左旋多巴+甲基多巴肼(延迟治疗组)。研究的主要终点为80周帕金森病统一评分差异(UPDRS,0-176)。次要终点为症状进展,比较提前治疗组4-40周、44-80周,延迟治疗组44-80周UPDRS得分差异,非劣性边界为周得分差异0.055分。

445名患者参与研究,其中早期治疗组222人,延迟治疗组223人,基线UPDRS得分分别为28.1和29.3分。80周各组UPDRS分别变化了-1.0±13.1分和-2.0±13.0分,无显著性差异,左旋多巴无疾病治疗效果。早期治疗组4-40周,每周UPDRS得分增加0.04±0.23,44-80周为0.10±0.25,延迟治疗组44-80周每周UPDRS得分增加0.03±0.28,表现出非劣性。组间患者运动障碍和左旋多巴相关运动反应无显著性差异。

研究认为,左旋多巴联合甲基多巴肼对早期帕金森患者无疾病治疗作用。

原始出处:

Constant V.M. Verschuur et al. Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.N Engl J Med,January 24, 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=361552, encodeId=8c38361552cc, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Feb 26 19:13:37 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360054, encodeId=26fe36005420, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Feb 06 14:43:13 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406656, encodeId=3424140665665, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Sat Jan 26 04:57:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604266, encodeId=121b1604266d6, content=<a href='/topic/show?id=e5de481095a' target=_blank style='color:#2F92EE;'>#左旋多巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48109, encryptionId=e5de481095a, topicName=左旋多巴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd6f19156562, createdName=jktdtl, createdTime=Sat Jan 26 04:57:00 CST 2019, time=2019-01-26, status=1, ipAttribution=)]
    2019-02-26 wxl882001

    了解一下

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=361552, encodeId=8c38361552cc, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Feb 26 19:13:37 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360054, encodeId=26fe36005420, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Feb 06 14:43:13 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406656, encodeId=3424140665665, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Sat Jan 26 04:57:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604266, encodeId=121b1604266d6, content=<a href='/topic/show?id=e5de481095a' target=_blank style='color:#2F92EE;'>#左旋多巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48109, encryptionId=e5de481095a, topicName=左旋多巴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd6f19156562, createdName=jktdtl, createdTime=Sat Jan 26 04:57:00 CST 2019, time=2019-01-26, status=1, ipAttribution=)]
    2019-02-06 wxl882001

    了解一下

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=361552, encodeId=8c38361552cc, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Feb 26 19:13:37 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360054, encodeId=26fe36005420, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Feb 06 14:43:13 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406656, encodeId=3424140665665, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Sat Jan 26 04:57:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604266, encodeId=121b1604266d6, content=<a href='/topic/show?id=e5de481095a' target=_blank style='color:#2F92EE;'>#左旋多巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48109, encryptionId=e5de481095a, topicName=左旋多巴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd6f19156562, createdName=jktdtl, createdTime=Sat Jan 26 04:57:00 CST 2019, time=2019-01-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=361552, encodeId=8c38361552cc, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Feb 26 19:13:37 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360054, encodeId=26fe36005420, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Feb 06 14:43:13 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406656, encodeId=3424140665665, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Sat Jan 26 04:57:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604266, encodeId=121b1604266d6, content=<a href='/topic/show?id=e5de481095a' target=_blank style='color:#2F92EE;'>#左旋多巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48109, encryptionId=e5de481095a, topicName=左旋多巴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd6f19156562, createdName=jktdtl, createdTime=Sat Jan 26 04:57:00 CST 2019, time=2019-01-26, status=1, ipAttribution=)]

相关资讯

Sci Transl Med:重磅!《Science》子刊:有望从基因层面治愈帕金森病

近日,来自Feinstein医学研究所的David Eidelberg教授领导的研究团队发现新型基因疗法可大大改善帕金森患者的临床症状,其最新的研究成果发表于《Science Translational Medicine》杂志。

FDA批准Acorda的Inbrija治疗帕金森病

Acorda公司近日表示,FDA已经批准其Inbrija(左旋多巴)作为帕金森病患者的间歇性治疗药物。根据Acorda的说法,Inbrija预计将于2019年第一季度在美国上市,并将通过专业药店网络进行分销。

PNAS:帕金森病的潜在抑制剂被发现

这提高了O-GlcNAc可能改变该蛋白质聚集的可能性。这些可能既是神经变性的重要生物介质,也是治疗靶标。

日本首次利用iPS细胞治疗人类帕金森病

日本京都大学9日宣布,该校研究人员已经开展了利用诱导多能干细胞(iPS细胞)治疗帕金森病的临床试验,向一名患者脑部移植了由iPS细胞培养的神经祖细胞。这种疗法在全球尚属首次使用。

Nature:全球首例移植干细胞治疗帕金森的人体试验启动

帕金森研究领域迎来新突破!据《Nature》杂志封面14日的报道,日本京都大学的科学家首次利用人类诱导多能干细胞(iPS细胞)制作的神经细胞对帕金森病患者进行移植治疗。据悉,该手术于上个月进行,是试验帕金森病新疗法的一个里程碑式的进步。

Front Neurosci:一石二鸟!咖啡竟可防帕金森和老年痴呆!

。近几年的研究发现,咖啡这种神奇的饮品对于预防各种疾病都有很好的作用,从预防心脏病到降低抑郁的发生,都能看到研究咖啡具有保护作用的文章。最新的研究发现,长喝咖啡竟然能够预防老年后帕金森的发病,这对众多咖啡依赖者来说又多了一个好事,这项研究的最新进展发表于近期的《Frontiers in Neuroscience》杂志。